Compare AU
Compare DRUG vs. WEMG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the SPDR S&P Emerging Markets Carbon Control Fund (WEMG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | WEMG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 4 |
Median incremental investment | $920.50 | $3,000.00 |
Median investment frequency | Monthly | Weekly |
Median total investment | $1,892.10 | $3,389.10 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | WEMG | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | WEMG.AX was created on 2013-11-11 by SPDR. The fund's investment portfolio concentrates primarily on total market equity. The SPDR S&P Emerging Market Fund seeks to closely track, before fees and expenses, the returns of the S&P Emerging Markets LargeMidCap Index. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Taiwan Semiconductor Manufacturing Co Ltd (7.88 %) Alibaba Group Holding Ltd Ordinary Shares (2.62 %) HDFC Bank Ltd (1.78 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Information Technology (48.64 %) Other (25.54 %) Consumer Discretionary (12.77 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | China (30.97 %) Taiwan (23.47 %) India (20.15 %) |
Management fee | 0.57 % | 0.35 % |
Key Summary
DRUG | WEMG | |
|---|---|---|
Issuer | BetaShares | SPDR |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P Emerging LargeMidCap AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.35 % |
Price | $7.95 | $26.07 |
Size | $185.172 million | $22.680 million |
10Y return | N/A | 51.04 % |
Annual distribution yield (5Y) | 1.90 % | 2.46 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 04/11/2013 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | WEMG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 4 |
Median incremental investment | $920.50 | $3,000.00 |
Median investment frequency | Monthly | Weekly |
Median total investment | $1,892.10 | $3,389.10 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | WEMG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | WEMG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |